SG11201901961SA - Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x - Google Patents
Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor xInfo
- Publication number
- SG11201901961SA SG11201901961SA SG11201901961SA SG11201901961SA SG11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA
- Authority
- SG
- Singapore
- Prior art keywords
- coagulation factor
- bleeding
- international
- activated
- recognizes
- Prior art date
Links
- 108010076282 Factor IX Proteins 0.000 title abstract 5
- 108010014173 Factor X Proteins 0.000 title abstract 4
- 229940105774 coagulation factor ix Drugs 0.000 title abstract 4
- 102100029117 Coagulation factor X Human genes 0.000 title abstract 3
- 229940105756 coagulation factor x Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 102000013831 Coagulation factor IX Human genes 0.000 title 2
- 230000000740 bleeding effect Effects 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010048049 Factor IXa Proteins 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111111111H11111110111011111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/047813 Al 15 March 2018 (15.03.2018) WIP0 I PCT (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 39/395 (2006.01) A61P 7/04 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/JP2017/031933 Declarations under Rule 4.17: (22) International Filing Date: — as to applicant's entitlement to apply for and be granted a 05 September 2017 (05.09.2017) patent (Rule 4.17(ii)) (25) Filing Language: English Published: (26) Publication Language: English — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (30) Priority Data: 62/383,933 06 September 2016 (06.09.2016) US 62/437,281 21 December 2016 (21.12.2016) US 62/485,514 14 April 2017 (14.04.2017) US (71) Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA [JP/JP]; 5-1, Ukima 5-chome, Kita-ku, Tokyo, 1158543 (JP). F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, Basel, CH4070 (CH). (72) Inventors: YONEYAMA, Koichiro; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 1-1, Nihon- bashi-Muromachi 2-chome, Chuo-ku, Tokyo, 1038324 (JP). SCHMITT, Christophe; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, Basel, CH4070 (CH). = (74) Agent: HARUNA, Masao et al.; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki, 3000847 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RS, RU, RW, SA, QA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated (84) States (unless otherwise indicated, for every kind of regional available): ARIPO (BW, GH, protection GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian AZ, BY, KG, KZ, RU, TJ, (AM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 en (54) Title: METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND/OR - ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND/OR ACTIVATED COAGULATION FAC- GC TOR X IN C (57) : An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for ---- preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that GC by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation 1-1 © factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X N according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented 0 and/or treated more effectively.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383933P | 2016-09-06 | 2016-09-06 | |
| US201662437281P | 2016-12-21 | 2016-12-21 | |
| US201762485514P | 2017-04-14 | 2017-04-14 | |
| PCT/JP2017/031933 WO2018047813A1 (en) | 2016-09-06 | 2017-09-05 | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901961SA true SG11201901961SA (en) | 2019-04-29 |
Family
ID=61561893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901961SA SG11201901961SA (en) | 2016-09-06 | 2017-09-05 | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US11352438B2 (en) |
| EP (1) | EP3509637A4 (en) |
| JP (2) | JP7125932B2 (en) |
| KR (2) | KR102560808B1 (en) |
| CN (1) | CN109661241A (en) |
| AU (1) | AU2017325240A1 (en) |
| BR (1) | BR112019003989A2 (en) |
| CA (1) | CA3035327A1 (en) |
| CR (1) | CR20190162A (en) |
| IL (1) | IL265144B1 (en) |
| MA (1) | MA46200A (en) |
| MX (1) | MX2019002510A (en) |
| RU (1) | RU2766233C2 (en) |
| SG (1) | SG11201901961SA (en) |
| TW (1) | TWI786061B (en) |
| WO (1) | WO2018047813A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609698B (en) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody-containing solution preparation |
| EP2644698B1 (en) | 2010-11-17 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| MX2019002510A (en) | 2016-09-06 | 2019-06-24 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x. |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| EP3710486A1 (en) | 2017-11-15 | 2020-09-23 | Novo Nordisk A/S | Factor x binders enhancing fx activation |
| FR3082427B1 (en) | 2018-06-14 | 2020-09-25 | Lab Francais Du Fractionnement | COMBINATION OF FACTOR VII AND A BISPECIFIC ANTIBODY ANTI-FACTORS IX AND X |
| JP2022515770A (en) | 2018-12-21 | 2022-02-22 | カイマブ・リミテッド | FIXa x FX bispecific antibody with common light chain |
| CN114599391A (en) * | 2019-10-11 | 2022-06-07 | 中外制药株式会社 | Pharmaceutical composition useful for preventing and/or treating acquired hemophilia a, and product comprising said pharmaceutical composition |
| TWI745114B (en) * | 2019-10-11 | 2021-11-01 | 日商中外製藥股份有限公司 | Pharmaceutical composition for the prevention and/or treatment of acquired hemophilia A, and products containing the pharmaceutical composition |
| USD967377S1 (en) | 2020-10-08 | 2022-10-18 | Samsung Electronics Co., Ltd. | Air purifier |
| KR20230130560A (en) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Methods of administering fviii mimetic bispecidic antibodies once weekly |
| KR20230130558A (en) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Methods of administering fviii mimetic bispecidic antibodies once monthly |
| KR20230130561A (en) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Methods of administering fviii mimetic bispecidic antibodies every second week |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| IL89491A0 (en) | 1988-11-17 | 1989-09-10 | Hybritech Inc | Bifunctional chimeric antibodies |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| DE68928946T2 (en) | 1989-12-11 | 1999-10-21 | Immunomedics Inc | METHOD FOR DETECTING DIAGNOSTIC OR THERAPEUTIC AGENTS BY ANTIBODIES |
| TW212184B (en) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
| JPH05184383A (en) | 1990-06-19 | 1993-07-27 | Dainabotsuto Kk | Bispecific antibody |
| JPH05199894A (en) | 1990-08-20 | 1993-08-10 | Takeda Chem Ind Ltd | Bi-specific antibody and antibody-containing medicine |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH05304992A (en) | 1991-06-20 | 1993-11-19 | Takeda Chem Ind Ltd | Hybridoma-monoclonal antibody and medicine containing antibody |
| JPH06104071A (en) | 1991-08-30 | 1994-04-15 | Jasco Corp | Method for welding heating element ceramics |
| DK1136556T3 (en) | 1991-11-25 | 2005-10-03 | Enzon Inc | Process for the preparation of multivalent antigen-binding proteins |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| JPH05203652A (en) | 1992-01-28 | 1993-08-10 | Fuji Photo Film Co Ltd | Antibody enzyme immunoassay |
| JPH05213775A (en) | 1992-02-05 | 1993-08-24 | Otsuka Pharmaceut Co Ltd | Bfa antibody |
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1995001571A1 (en) | 1993-07-01 | 1995-01-12 | Baxter Diagnostics Inc. | Process for the preparation of factor x depleted plasma |
| FR2707189B1 (en) | 1993-07-09 | 1995-10-13 | Gradient Ass | Method for treating combustion residues and installation for implementing said method. |
| WO1996001653A1 (en) | 1994-07-11 | 1996-01-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| WO1996002576A1 (en) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| AU4289496A (en) | 1994-12-02 | 1996-06-19 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| MA24512A1 (en) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | PROCESS FOR THE PREPARATION OF ANTICOAGULATING AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS |
| JP3032287U (en) | 1996-06-10 | 1996-12-17 | 幸喜 高橋 | Human form |
| JPH10165184A (en) | 1996-12-16 | 1998-06-23 | Tosoh Corp | Antibody, gene and production of chimera antibody |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| ES2246069T3 (en) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS. |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| DE19725586C2 (en) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Process for the preparation of cell preparations for immunization by means of heterologous intact bispecific and / or trispecific antibodies |
| US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| HUP0101160A2 (en) | 1998-04-03 | 2001-08-28 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
| AT411997B (en) | 1999-09-14 | 2004-08-26 | Baxter Ag | FACTOR IX / FACTOR IXA ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES |
| JP2004511430A (en) | 2000-05-24 | 2004-04-15 | イムクローン システムズ インコーポレイティド | Bispecific immunoglobulin-like antigen binding protein and production method |
| EP1304573A4 (en) | 2000-07-17 | 2006-06-07 | Chugai Pharmaceutical Co Ltd | Method for screening ligand having biological activity |
| CA2421447C (en) | 2000-09-08 | 2012-05-08 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| DE60139944D1 (en) | 2000-10-12 | 2009-10-29 | Genentech Inc | LOW VISCOSIS CONCENTRATED PROTEIN FORMULATIONS |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| WO2002033073A1 (en) | 2000-10-20 | 2002-04-25 | Chugai Seiyaku Kabushiki Kaisha | Degraded agonist antibody |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
| DE10156482A1 (en) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispecific antibody molecule |
| WO2003087163A1 (en) | 2002-04-15 | 2003-10-23 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF CONSTRUCTING scDb LIBRARY |
| US7732149B2 (en) | 2002-04-26 | 2010-06-08 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening agonistic antibodies |
| CA2872136C (en) | 2002-07-18 | 2017-06-20 | Merus B.V. | Recombinant production of mixtures of antibodies |
| JPWO2004060919A1 (en) | 2002-12-26 | 2006-05-11 | 中外製薬株式会社 | Agonist antibodies against heteroreceptors |
| DE602004021095D1 (en) | 2003-01-21 | 2009-06-25 | Chugai Pharmaceutical Co Ltd | METHOD OF SCREENING THE LIGHT CHAIN OF AN ANTIBODY |
| JP4607010B2 (en) | 2003-02-28 | 2011-01-05 | 中外製薬株式会社 | Protein-containing stabilized preparation |
| GB2400851B (en) | 2003-04-25 | 2004-12-15 | Bioinvent Int Ab | Identifying binding of a polypeptide to a polypeptide target |
| JP4794301B2 (en) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | Antibody production method |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| JPWO2005035754A1 (en) | 2003-10-14 | 2006-12-21 | 中外製薬株式会社 | Bispecific antibodies that replace functional proteins |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| JP4460414B2 (en) | 2004-10-06 | 2010-05-12 | 日本電信電話株式会社 | Sphygmomanometer |
| TWI671403B (en) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | Method for controlling controlled assembly of polypeptide |
| SI1876236T1 (en) | 2005-04-08 | 2014-11-28 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| WO2007114325A1 (en) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| MX369784B (en) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Method of modifying isoelectric point of antibody via amino acid substitution in cdr. |
| PE20091174A1 (en) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT |
| MX2012007497A (en) | 2009-12-25 | 2012-08-01 | Chugai Pharmaceutical Co Ltd | Polypeptide modification method for purifying polypeptide multimers. |
| TWI609698B (en) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody-containing solution preparation |
| CA2802072A1 (en) | 2010-06-14 | 2011-12-22 | Paion Deutschland Gmbh | Treatment of coagulopathy with hyperfibrinolysis |
| EP2644698B1 (en) | 2010-11-17 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| KR101666289B1 (en) | 2012-03-08 | 2016-10-13 | 에프. 호프만-라 로슈 아게 | Abeta antibody formulation |
| BR112016009954A2 (en) | 2013-11-04 | 2017-12-05 | Univ California | therapy for the treatment or prevention of conditions associated with hypocoagulation bleeding |
| TWI831106B (en) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | Pharmaceutical compositions for the prevention and/or treatment of diseases that develop and/or progress due to reduced or deficient activity of coagulation factor VIII and/or activated coagulation factor VIII |
| WO2016164708A1 (en) | 2015-04-10 | 2016-10-13 | Adimab, Llc | Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species |
| CA2978038A1 (en) | 2015-04-17 | 2016-10-20 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
| JP2018123055A (en) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | Pharmaceutical composition for use in prevention and/or treatment of blood coagulation factor xi (fxi) abnormalities comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii (fviii) |
| TWI797073B (en) | 2016-01-25 | 2023-04-01 | 德商安美基研究（慕尼黑）公司 | Pharmaceutical composition comprising bispecific antibody constructs |
| TW202402326A (en) | 2016-04-28 | 2024-01-16 | 日商中外製藥股份有限公司 | Antibody-containing preparation |
| MX2019002510A (en) | 2016-09-06 | 2019-06-24 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x. |
| CN110461358A (en) | 2017-03-31 | 2019-11-15 | 公立大学法人奈良县立医科大学 | It can be used for preventing and/or treating the pharmaceutical composition of the polyspecific antigen binding molecules of the abnormal function comprising replacing platelet cofactor Ⅰ of factor IX |
| CN111479829A (en) | 2017-11-01 | 2020-07-31 | 中外制药株式会社 | Antibody variants and isotypes with reduced biological activity |
| TWI745114B (en) | 2019-10-11 | 2021-11-01 | 日商中外製藥股份有限公司 | Pharmaceutical composition for the prevention and/or treatment of acquired hemophilia A, and products containing the pharmaceutical composition |
-
2017
- 2017-09-05 MX MX2019002510A patent/MX2019002510A/en unknown
- 2017-09-05 CN CN201780054106.1A patent/CN109661241A/en active Pending
- 2017-09-05 US US16/330,269 patent/US11352438B2/en active Active
- 2017-09-05 RU RU2019109464A patent/RU2766233C2/en active
- 2017-09-05 AU AU2017325240A patent/AU2017325240A1/en active Pending
- 2017-09-05 CA CA3035327A patent/CA3035327A1/en active Pending
- 2017-09-05 SG SG11201901961SA patent/SG11201901961SA/en unknown
- 2017-09-05 TW TW106130277A patent/TWI786061B/en active
- 2017-09-05 WO PCT/JP2017/031933 patent/WO2018047813A1/en unknown
- 2017-09-05 MA MA046200A patent/MA46200A/en unknown
- 2017-09-05 EP EP17848753.4A patent/EP3509637A4/en active Pending
- 2017-09-05 BR BR112019003989A patent/BR112019003989A2/en unknown
- 2017-09-05 KR KR1020197009689A patent/KR102560808B1/en active IP Right Grant
- 2017-09-05 KR KR1020237025275A patent/KR20230117462A/en not_active Application Discontinuation
- 2017-09-05 IL IL265144A patent/IL265144B1/en unknown
- 2017-09-05 JP JP2019511669A patent/JP7125932B2/en active Active
- 2017-09-05 CR CR20190162A patent/CR20190162A/en unknown
-
2022
- 2022-05-31 US US17/828,752 patent/US20220315667A1/en not_active Abandoned
- 2022-08-15 JP JP2022129184A patent/JP2022166174A/en active Pending
-
2023
- 2023-01-19 US US18/156,559 patent/US20230159658A1/en not_active Abandoned
- 2023-09-14 US US18/466,900 patent/US20240052058A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019530654A (en) | 2019-10-24 |
| JP2022166174A (en) | 2022-11-01 |
| CR20190162A (en) | 2019-05-13 |
| MA46200A (en) | 2019-07-17 |
| RU2019109464A (en) | 2020-10-08 |
| US20190194352A1 (en) | 2019-06-27 |
| WO2018047813A1 (en) | 2018-03-15 |
| IL265144B1 (en) | 2024-06-01 |
| MX2019002510A (en) | 2019-06-24 |
| AU2017325240A1 (en) | 2019-05-02 |
| TW201822815A (en) | 2018-07-01 |
| BR112019003989A2 (en) | 2019-05-28 |
| US20230159658A1 (en) | 2023-05-25 |
| EP3509637A4 (en) | 2020-05-27 |
| IL265144A (en) | 2019-04-30 |
| US20220315667A1 (en) | 2022-10-06 |
| JP7125932B2 (en) | 2022-08-25 |
| KR102560808B1 (en) | 2023-07-27 |
| RU2766233C2 (en) | 2022-02-10 |
| CA3035327A1 (en) | 2018-03-15 |
| US11352438B2 (en) | 2022-06-07 |
| CN109661241A (en) | 2019-04-19 |
| RU2019109464A3 (en) | 2020-12-21 |
| EP3509637A1 (en) | 2019-07-17 |
| TWI786061B (en) | 2022-12-11 |
| KR20190044673A (en) | 2019-04-30 |
| KR20230117462A (en) | 2023-08-08 |
| US20240052058A1 (en) | 2024-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201801401UA (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201805420SA (en) | Antibodies and conjugates thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201805001UA (en) | Method of treating influenza a |